Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor Efficacy-Reference-Cited by-同舟云学术

Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor Efficacy

Published:2010-08 Issue:8 Volume:9 Page:2243-2254
ISSN:1535-7163
Container-title:Molecular Cancer Therapeutics
language:en
Short-container-title:Mol Cancer Ther

Author:

Albanese Clara,Alzani Rachele,Amboldi Nadia,Avanzi Nilla,Ballinari Dario,Brasca Maria Gabriella,Festuccia Claudio,Fiorentini Francesco,Locatelli Giuseppe,Pastori Wilma,Patton Veronica,Roletto Fulvia,Colotta Francesco,Galvani Arturo,Isacchi Antonella,Moll Jurgen,Pesenti Enrico,Mercurio Ciro,Ciomei Marina

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CACTI: an in silico chemical analysis tool through the integration of chemogenomic data and clustering analysis;Journal of Cheminformatics;2024-07-24

2. CACTI: An in-silicodrug-target prediction tool through the integration of chemogenomic data and clustering analysis;2024-02-24

3. IFIH1-mediated post-transcriptional regulation of PTTG1 promotes proliferation and affects PHA-848125 sensitivity and prognosis in oropharyngeal carcinoma;American Journal of Cancer Research;2024

4. Classification models for predicting the bioactivity of pan-TRK inhibitors and SAR analysis;Molecular Diversity;2023-11-01

5. Structural Insights into N-heterocyclic Moieties as an Anticancer Agent against Hepatocellular Carcinoma: An Exhaustive Perspective;Mini-Reviews in Medicinal Chemistry;2023-10